Creates a wholesale prescription drug importation program which complies with federal standards and regulations for the purpose of generating substantial savings for consumers.
S00371 would create a New York wholesale prescription drug importation program designed to allow approved wholesalers to import certain prescription drugs from Canada for resale in the state. The program is intended to lower drug costs for consumers, but it is tightly limited: imported drugs must meet federal safety and labeling standards, come from regulated Canadian suppliers, and be expected to produce substantial savings. The bill excludes several categories of drugs, including controlled substances, biological products, infused and intravenous drugs, and certain other drugs that federal officials determine could pose public-health risks.
The bill directs the Commissioner of Health, in consultation with the Education Department and other agencies, to design the program, seek federal approval and certification, and adopt rules and regulations. It also requires participating wholesalers to be approved by the State Education Department, comply with track-and-trace requirements, provide detailed reporting on imported drugs and pricing, and pay an annual fee that may help fund the program. The bill further requires auditing, annual reporting to state leaders, and immediate suspension of any drug or wholesaler found to be violating state or federal law.
In terms of state-law impact, the bill amends both the Public Health Law and the Education Law. It adds a new Public Health Law section establishing the importation framework and a new Education Law provision requiring wholesalers to apply for and receive department approval before participating. The measure also contemplates coordination with federal law, especially 21 U.S.C. § 384, and seeks waivers or other approvals so that entities involved in the federal 340B drug discount program can participate without losing eligibility.
The overall sentiment reflected in the voting history is strongly favorable, with unanimous or near-unanimous committee support and large bipartisan floor majorities. That pattern suggests broad agreement on the goal of reducing prescription drug costs through regulated importation. The bill’s structure also indicates a cautious approach, emphasizing federal compliance, safety controls, and oversight rather than unrestricted importation.
The main points of contention are likely to center on implementation and federal approval rather than the concept itself. Potential concerns include whether the program can actually secure the necessary federal certifications, whether imported drugs can be reliably tracked and verified, whether the expected savings will materialize, and how the program might affect wholesalers, regulators, and 340B-covered entities. The bill’s exclusions for certain drug types and its suspension authority also reflect concerns about public health and regulatory risk.
The bill would add a new wholesale prescription drug importation program to the Public Health Law and create a related wholesaler-approval process in the Education Law. It would authorize the Department of Health, working with the Education Department, to regulate Canadian importation of certain prescription drugs, impose fees, require reporting and audits, and suspend noncompliant imports or wholesalers. The measure would affect prescription drug wholesalers, Canadian suppliers, state regulators, and consumers seeking lower drug prices, while leaving federal approval as a prerequisite to implementation.
The available voting record shows strong support for the bill, with unanimous committee votes and large bipartisan majorities on the Senate floor. That suggests the proposal is broadly viewed as a consumer-cost relief measure with significant appeal across party lines. The support appears to be driven by the promise of lower prescription drug prices, tempered by a regulatory framework intended to address safety and compliance concerns.
There is little evidence of overt opposition in the provided materials, but the likely areas of concern are practical and legal rather than ideological. The biggest issues are whether New York can obtain the required federal approvals, whether the importation system can be administered safely and transparently, and whether the projected consumer savings will be substantial. Additional concerns involve the effect on 340B participants, the burden on wholesalers and regulators, and the possibility that certain drugs or wholesalers may need to be suspended if compliance problems arise.